IVERIC bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ISEE research report →
Range $27 – $35
Price Chart
About the company
IVERIC bio, Inc. is a biopharmaceutical enterprise focused on identifying and advancing innovative therapeutic solutions for eye conditions, with a particular emphasis on age-related and rare inherited retinal diseases (IRDs). A cornerstone of its development pipeline is Zimura, an inhibitor targeting complement factor C5.
- CEO
- Glenn P. Sblendorio
- IPO
- 2013
- Employees
- 163
- HQ
- Parsippany, NJ, US
Get TickerSpark's AI analysis on ISEE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.51B
- P/E
- -27.55
- PEG
- 0.71
- P/S
- 0.00
- P/B
- 9.04
- EV/EBITDA
- -28.08
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -39.26%
- ROIC
- -28.49%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-189,906,000
- Net Income
- $-175,745,000-53.8%
- EPS
- $-1.45-29.5%
- OCF Growth
- -66.2%
- FCF Growth
- -66.3%
- 52W High
- $39.99
- 52W Low
- $9.39
- 50D MA
- $38.02
- 200D MA
- $26.09
- Beta
- 1.10
- RSI (14)
- 69
- Avg Volume
- 4.95M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
IVERIC Bio said ACP’s NDA is under FDA priority review with an August 19 PDUFA date, while new post hoc data suggested less vision loss at 12 months and the company continued building for a potential U.S. launch.· March 1, 2023
- ACP’s NDA was accepted and granted priority review, with a PDUFA date of August 19, 2023 and no advisory committee currently planned.
- Management highlighted a post hoc analysis showing up to 59% risk reduction in vision loss vs. sham at 12 months for ACP 2 mg.
- The company is preparing a U.S. launch, aiming for a full U.S. team by early April and a sales force of about 50 to 70 reps.
- Cash was strengthened by about $324.3 million of net proceeds from an equity raise and a $250 million term loan facility, with $100 million drawn to date.
- Management said it does not plan a new intermediate AMD trial and intends to pursue further FDA and ex-U.S. discussions using the existing GATHER data.
For Q4 2022, net loss was $59.1 million, or $0.47 per share, versus a net loss of $33 million, or $0.29 per share in Q4 2021. For full-year 2022, net loss was $185.2 million, or $1.53 per share, versus a net loss of $114.5 million, or $1.12 per share in 2021. Management said the higher loss was driven by increased R&D and G&A, including GATHER2 progress, ACP manufacturing, and commercial launch preparation. As of December 31, cash, cash equivalents and available-for-sale securities were about $646.8 million. The company said it believes it has resources to launch ACP in the U.S. if approved and cover planned capital expenditures, debt service, and operating expenses for at least the next 12 months; this excludes any additional borrowings beyond the $25 million planned for 2023 and the possible additional $75 million available after approval.
Glenn Sblendorio framed 2022 as a year of major execution, citing positive Phase 3 data, NDA filing completion, breakthrough designation, and now priority review. His tone was upbeat and focused on readiness: the company is accelerating commercial buildout and wants to be prepared to launch ACP quickly if approved. He also emphasized broader lifecycle and market-expansion efforts, including discussions with regulators about intermediate AMD and ongoing sustained-delivery work.
David Carroll focused on the loss widening from prior year, attributing it mainly to higher R&D and G&A. He gave specific cash and financing figures: $646.8 million in cash, cash equivalents and available-for-sale securities at December 31, $324.3 million in net proceeds from the equity offering, and a $250 million term loan facility with $100 million drawn. He said the company expects enough financial resources for at least the next 12 months and noted $25 million of additional borrowings planned in 2023, with another $75 million potentially available upon approval.
Analysts pressed on whether the new vision-loss analysis could influence labeling or support a functional claim; management repeatedly said it is an exploratory post hoc analysis and declined to speculate on FDA labeling discussions. They also asked about target populations, dosing, and the 1.5 million to 2 million U.S. patient market; management said all GA patients could be considered in practice, but real-world dosing will likely be driven by patient ability to come in rather than label language. On commercialization, management said a permanent J code would likely be filed at the first quarterly opportunity after an August approval, with receipt expected in early second quarter 2024.
The call gave multiple signs of regulatory and commercial momentum: NDA acceptance, priority review, no advisory committee currently planned, and management’s confidence in FDA interactions. The post hoc vision-loss signal, plus continued work on ex-U.S. discussions and commercial readiness, supports the case that ACP could have a meaningful launch opportunity if approved.
The vision-loss data were explicitly described as post hoc, exploratory, and not part of the primary regulatory package, so their label impact is uncertain. The company also faces launch and execution risk, including the need to build a large sales organization quickly, educate upstream eye-care providers, and wait for the FDA decision on August 19, 2023.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.3%
- Shares Outstanding
- 137.98M
- Float Shares
- 137.02M
of shares held by institutions
319 13F filers
Buy/sell ratio 0.01. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ISEE, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Monarch Partners Asset Management LLC | 186.71K | ▲ 47.39K |
| Pictet Asset Management SA | 24.97K | ▼ 2.29M |
| Vident Investment Advisory, LLC | 22.29K | ▲ 22.29K |
| Jefferies Group LLC | 19.51K | ▲ 18.85K |
| Aevitas Wealth Management, Inc. | 17.77K | ▲ 100 |
| Gyon Technologies Capital Management, LP | 9.86K | ▼ 3.40K |
| Endurance Wealth Management, Inc. | 1.50K | ▼ 1.20K |
| Wipfli Financial Advisors LLC, | 39 | ▲ 39 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 11, 23 | Blumenkranz Mark S. | sell | 32,088 |
| Jul 11, 23 | Blumenkranz Mark S. | sell | 7,500 |
| Jul 11, 23 | Blumenkranz Mark S. | sell | 15,500 |
| Jul 11, 23 | Blumenkranz Mark S. | sell | 23,186 |
| Jul 11, 23 | Blumenkranz Mark S. | sell | 31,000 |
| Jul 11, 23 | Carroll David Francis | sell | 70,000 |
| Jul 11, 23 | Carroll David Francis | sell | 38,000 |
| Jul 11, 23 | Carroll David Francis | sell | 115,000 |
| Jul 11, 23 | Carroll David Francis | sell | 150,000 |
| Jul 11, 23 | Carroll David Francis | sell | 75,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ISEE coverage
Recent articles, reports, and earnings notes.
No research on ISEE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ISEE report →Fujitsu, Nagoya University, JAMSTEC and NICT develop technology to automatically optimize parameters for solar energetic particle simulations
gurufocus.com · Oct 21
Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA)
prnewswire.com · Sep 20
Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
prnewswire.com · Sep 18
European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy
prnewswire.com · Aug 17
Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy
prnewswire.com · Aug 4
Deep Track Capital, LP Acquires New Stake in Terns Pharmaceuticals Inc
gurufocus.com · Jul 28
Astellas Completes Acquisition of Iveric Bio
prnewswire.com · Jul 11
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ISEE, MDWT, RXDX, UNVR
headlinesoftoday.com · May 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.